Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group.
10.3802/jgo.2015.26.4.277
- Author:
Jung Yun LEE
1
;
Kidong KIM
;
Taek Sang LEE
;
Sokbom KANG
;
Seok Ju SEONG
;
Jae Weon KIM
;
Byoung Gie KIM
Author Information
1. Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Adjuvant Therapy;
Data Collection;
Endometrial Neoplasms;
Lymph Node Excision;
Practice Pattern
- MeSH:
Adult;
Combined Modality Therapy;
Endometrial Neoplasms/pathology/*therapy;
Female;
*Gynecology;
Humans;
Incidental Findings;
Lymph Node Excision/methods;
Lymphatic Metastasis;
Magnetic Resonance Imaging/methods;
Male;
Middle Aged;
Neoadjuvant Therapy;
Personal Satisfaction;
Practice Patterns, Physicians';
Republic of Korea;
Robotic Surgical Procedures
- From:Journal of Gynecologic Oncology
2015;26(4):277-283
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To identify current practice patterns for unresolved issues in the surgical and adjuvant management of endometrial cancer in Korea. METHODS: We designed and conducted a survey of all 218 active members of the Korean Gynecologic Oncology Group to try to identify how they would manage various case scenarios for endometrial cancer. Data were collected using an Internet survey database. RESULTS: A total of 108 members (49.5%) responded to the survey. Laparoscopy (81.6%) was the most commonly used mode of surgery in early-stage endometrial cancer. Of all the respondents, 19.8% stated that lymphadenectomy could be omitted and 21.7% recommended selective lymphadenectomy based on sentinel biopsy or frozen results for patients with presumed stage IA/grade 1 disease. On the other hand, 71.9% of respondents recommended para-aortic lymphadenectomy for patients with presumed stage IB/grade 1 disease and 86.4% recommended this treatment for presumed stage IB/grade 3 disease. The majority of respondents performed adjuvant therapy for stage IB/grade 2 (91.7%), IB/grade 3 (99.0%), and stage II (89.6%). Whole pelvic radiotherapy and vaginal brachytherapy were the most frequently used options among these patients. All respondents administered adjuvant therapy when node metastasis was found, and concurrent chemoradiotherapy (53.2%) was the most preferred option for stage IIIC1 disease. CONCLUSION: There is broad variation in both the surgical and adjuvant treatment of endometrial cancer among Korean gynecologic oncologists.
